End-of-day quote
Other stock markets
|
||
- | - |
2023 | Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 5 billion in funding | CI |
2023 | Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 5 billion in funding | CI |
Sales 2022 | 5.9TCr 4.37Cr 0 363.4Cr | Sales 2023 | 6.84TCr 5.06Cr 0 421.57Cr | Capitalization | 5.99TCr 4.43Cr 0 368.74Cr |
---|---|---|---|---|---|
Net income 2022 | -677.9Cr -50.16L - -42Cr | Net income 2023 | -2.1TCr -1.55Cr - -129.32Cr | EV / Sales 2022 | 1.19 x |
Net cash position 2022 | 1.23TCr 90.91L 0 76Cr | Net Debt 2023 | 1.63TCr 1.21Cr 0 100.5Cr | EV / Sales 2023 | 1.11 x |
P/E ratio 2022 |
-11.5
x | P/E ratio 2023 |
-2.84
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.08% |
Managers | Title | Age | Since |
---|---|---|---|
Seong-Won Oh
CEO | Chief Executive Officer | 46 | - |
Seung-Jae Lim
AUD | Comptroller/Controller/Auditor | 77 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Byung-Jin Kim
BRD | Director/Board Member | 46 | - |
Seong-Won Oh
CEO | Chief Executive Officer | 46 | - |
Hyeon-Bo Yoon
BRD | Director/Board Member | 53 | - |
1st Jan change | Capi. | |
---|---|---|
+21.63% | 4.41TCr | |
+23.03% | 2.27TCr | |
+18.22% | 1.51TCr | |
+12.66% | 1.36TCr | |
+60.18% | 1.27TCr | |
-10.02% | 684.06Cr | |
-0.05% | 678.76Cr | |
-8.87% | 572.55Cr | |
+12.92% | 562.63Cr |